VEGFA and proliferative diabetic retinopathy: Their review included randomized clinical trials (RCTs) and “quasi” randomized trials on anti-VEGF, to evaluate the incidence of vitreous hemorrhage post-vitrectomy in patients with proliferative diabetic retinopathy.